This week in therapeutics




Licensing status

Publication and contact information


Solid tumors

TNF-like weak inducer of apoptosis receptor (TNFRSF12A; TWEAKR; FN14)

Mouse and cell culture studies identified an antibody-drug conjugate against FN14 that could help treat FN14+ solid tumors. In a panel of five FN14+ human breast cancer cell lines, a humanized, dimeric, single-chain anti-FN14 antibody fused to recombinant gelonin toxin was cytotoxic and had IC50 values of 0.1-2.4 nM. In a mouse xenograft model for FN14+ human breast cancer, the FN14-targeted immunotoxin significantly decreased tumor growth (p<0.01) and increased survival (p<0.0001) compared with saline. Next steps could include testing the targeted immunotoxin in other FN14+ solid tumors.

SciBX 6(27); doi:10.1038/scibx.2013.682
Published online July 18, 2013

Patent and licensing status unavailable

Zhou, H. et al. Cancer Res.; published online May 30, 2013;
Contact: Michael G. Rosenblum, The University of Texas MD Anderson Cancer Center, Houston, Texas